ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rotigotine

Also written as “Rotigotine”, “SPM 962” and “Rotigotine transdermal patch”.

Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Fibromyalgia, led by 5 companies.

Drug pageRotigotine: every studyMany companies study it; this page follows only the 63 they lead. All 77 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 21, 200763 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCBits history only500 open or runningphase 4since Dec 21, 2007Aug 24, 2005none ahead
Otsuka100 open or runningphase 3since Sep 27, 2007Sep 27, 2007none ahead
Eva Pharmaits history only11 open or runningno phasesince May 30, 2025May 30, 2025none ahead
Inflamax Researchits history only10 open or runningphase 1since Feb 25, 2016Feb 25, 2016none ahead
Luye Pharma Groupits history only10 open or runningphase 1since Mar 31, 2016Mar 31, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2007First study: phase 3 study in Parkinson DiseaseFirst studyNCT00537485 · 180 enrolled · Japan
  2. Apr 23, 2008Phase 2 study in Idiopathic Restless Legs SyndromeNCT00666965 · 230 enrolled · Japan
  3. Mar 4, 2010Phase 3 study in Idiopathic Restless Legs SyndromeNCT01084551 · 284 enrolled · Japan
  4. Mar 22, 2012Phase 2 study in Idiopathic Restless Legs SyndromeNCT01562743 · 185 enrolled
  5. Jun 24, 20123 phase 3 studies in Parkinson DiseaseNCT01628926, NCT01631825, NCT01628965
  6. Jun 24, 20123 phase 2 studies in Parkinson DiseaseNCT01628848, NCT01631812, NCT01634243

TargetBeta

“D2-like dopamine receptor agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476
PramipexoleruleBoehringer Ingelheimphase 444

Studies

All 10 Otsuka leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01634243Parkinson Disease · Japan2CompletedMay 200664
NCT01631825Parkinson Disease · Japan3CompletedJun 2012321
NCT01631812Parkinson Disease · Japan2CompletedFeb 2010130
NCT01628965Parkinson Disease · Japan3CompletedOct 2010143
NCT01628926Parkinson Disease · Japan3CompletedMay 2011420
NCT01628848Parkinson Disease · Japan2CompletedApr 2008174
NCT01562743Idiopathic Restless Legs Syndrome2CompletedOct 2010185
NCT01084551Idiopathic Restless Legs Syndrome · Japan3CompletedSep 2011284
NCT00666965Idiopathic Restless Legs Syndrome · Japan2CompletedAug 2009230
NCT00537485Parkinson Disease · Japan3CompletedDec 2009180

How it is read

Names in the registry

  • “Rotigotine”, 39 entries
  • “SPM 962”, 13 entries
  • “Rotigotine transdermal patch”, 4 entries
  • “Rotigexole 8 mg”, 1 entry
  • “Rotigotine 1 mg/24 h”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.